Sign in
Taking people in United StatesPhase 4

A Study to Learn About How 20-Valent Pneumococcal Conjugate Vaccine Works in a Real-world Setting

Key facts

Who runs it
Pfizer
Where
Akron, Atlanta, Baltimore, Beachwood, Clackamas, Cleveland, El Centro, Fontana, Greenville, Hartford, Hillsborough, Houston, Kenner, Los Angeles, Louisville, New Orleans, Oakland, Ontario, Pasadena, Riverside, Roseville, Sacramento, San Diego, Santa Clara, South San Francisco, Walnut Creek, Washington D.C., and Worcester, United StatesSee the 40 sitesAlso in 2 other countries, 19 sites
Status
Recruiting
Phase
Phase 4
People taking part
12,500 people, planned
Started
27 Oct 2022
Expected to end
4 Jun 2027
Type of study
Observational, 2 groups
Treatments tested
  • Diagnostic test on urine samples
Record updated
11 May 2026

Who can take part

Age
65 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Male or female participants ≥65 years of age
  • Hospitalized participant with physician clinical suspicion of CAP with the presence of ≥2 of the following 10 clinical signs or symptoms:; fever (oral temperature >38.0°C/100.4°F or tympanic temperature >38.5°C/101.2°F),; hypothermia (<35.5°C/95.9°F measured by a healthcare provider); chills or rigors,; pleuritic chest pain,; new or worsening cough,; sputum production,; dyspnea (shortness of breath),; tachypnea (respiratory rate >20/min),; malaise, or; abnormal auscultatory findings suggestive of pneumonia (rales or evidence of pulmonary consolidation including dullness on percussion, bronchial breath sounds, or egophony)
  • Has a radiographic finding that is consistent with pneumonia (e.g., pleural effusion, increased pulmonary density due to infection, the presence of alveolar infiltrates [multi-lobar, lobar, or segmental] containing air bronchograms)
  • Capable of giving signed informed consent

Who cannot take part

  • Received any pneumococcal vaccine ≤30 days prior to enrollment
  • Previous enrollment in the study within the past 30 days
  • Any participant who develops signs and symptoms of pneumonia after being hospitalized for ≥48 hours (either at the study site, another transferring hospital, or a combination of these)
  • Unable to provide urine specimen (e.g. anuric)

Where in United States

Also in 2 other countries, 19 sites

  • Summa HealthAkron, United StatesTaking people
  • Summa Health Clinical Research Center - SpecialtyAkron, United StatesTaking people
  • Emory Children's Center - Vaccine Research Clinic (ECC-VRC)Atlanta, United StatesTaking people
  • Emory University HospitalAtlanta, United StatesTaking people
  • University of MarylandBaltimore, United StatesTaking people
  • Ahuja Medical CenterBeachwood, United StatesTaking people
  • Kaiser Permanente Sunnyside Medical CenterClackamas, United StatesTaking people
  • University Hospitals Cleveland Medical Center*Cleveland, United StatesTaking people
  • El Centro Regional Medical CenterEl Centro, United StatesTaking people
  • Kaiser Permanente Fontana Medical CenterFontana, United StatesTaking people
  • ECU Health Medical CenterGreenville, United StatesTaking people
  • Starling PhysiciansHartford, United StatesNo longer taking part
  • UNC Hospitals Hillsborough CampusHillsborough, United StatesTaking people
  • Memorial Hermann HospitalHouston, United StatesTaking people
  • Michael E. DeBakey VA Medical CenterHouston, United StatesTaking people
  • Ochsner Medical Center KennerKenner, United StatesTaking people
  • Kaiser Permanente West Los Angeles Medical CenterLos Angeles, United StatesTaking people
  • Norton Audubon HospitalLouisville, United StatesTaking people
  • Norton Brownsboro HospitalLouisville, United StatesTaking people
  • Norton Women's and Children's HospitalLouisville, United StatesTaking people
  • Robley Rex VA Medical CenterLouisville, United StatesTaking people
  • University of Louisville School of Medicine, Division of Infectious DiseasesLouisville, United StatesTaking people
  • UofL Health, Mary & Elizabeth HospitalLouisville, United StatesTaking people
  • Ochsner Baptist Medical CenterNew Orleans, United StatesTaking people
  • Ochsner Clinic FoundationNew Orleans, United StatesTaking people
  • Kaiser Permanente Oakland Medical CenterOakland, United StatesTaking people
  • Kaiser Permanente Vaccine Study CenterOakland, United StatesTaking people
  • Kaiser Permanente Ontario Medical CenterOntario, United StatesTaking people
  • Southern California Permanente Medical Group (SCPMG)Pasadena, United StatesTaking people
  • Kaiser Permanente Riverside Medical CenterRiverside, United StatesTaking people
  • Kaiser Permanente Roseville Medical CenterRoseville, United StatesTaking people
  • Kaiser Permanente Sacramento Medical CenterSacramento, United StatesTaking people
  • Kaiser Permanente South Sacramento Medical CenterSacramento, United StatesTaking people
  • Kaiser Permanente San Diego medical CenterSan Diego, United StatesTaking people
  • Kaiser Permanente Zion Medical CenterSan Diego, United StatesTaking people
  • Kaiser Permanente Santa Clara Medical CenterSanta Clara, United StatesTaking people
  • Kaiser Permanente - South San Francisco Medical CenterSouth San Francisco, United StatesTaking people
  • Kaiser Permanente Walnut Creek Medical CenterWalnut Creek, United StatesTaking people
  • MedStar Washington Hospital CenterWashington D.C., United StatesTaking people
  • Umass Memorial Medical CenterWorcester, United StatesTaking people

About the trial

What the trial wants to find out

The purpose of this study is to learn about how well the 20-valent pneumococcal conjugate vaccine (20vPnC) works against radiologically-confirmed community-acquired pneumonia (RAD+CAP) due to the 7 new serotypes (types of a bacteria called Streptococcus pneumoniae that cause pneumonia) included in 20vPnC vaccine.

Read full original descriptionShow less

This study is seeking participants who:

* are male or female ≥65 years of age. * are hospitalized with physician suspicion of community acquired pneumonia (CAP). * have pneumonia confirmed with imaging like a chest x-ray

Participants will be asked to provide demographic and medical history information, and to provide a urine sample that will be used to test for pneumonia caused by specific strains of a bacteria called Streptococcus pneumoniae. We will compare the proportion of participants who have pneumonia caused by specific strains of the bacteria Streptococcus pneumoniae and were previously vaccinated with 20vPnC with the proportion of participants who have pneumonia caused by something other than vaccine type Streptococcus pneumoniae and have been vaccinated with 20vPnC. Participants will actively take part in the study for about 1-2 days. Information on participant's illness and hospitalization details will be collected through day 30 of their hospitalization through medical chart review.

The 2 groups in the trial

  • Case

    Cases will be defined as participants hospitalized for RAD+CAP in whom the 7 additional serotypes in 20vPnC beyond 13vPnC plus 15C are identified.

    Treatment: Diagnostic test on urine samples

  • Control

    All other participants who meet study inclusion criteria but for whom 20vPnC serotypes are not identified from any source and all other RAD+CAP of non-pneumococcal etiologies will serve as test-negative controls.

    Treatment: Diagnostic test on urine samples

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase 4 Study Using a Test-Negative Design to Evaluate the Effectiveness of a 20-valent Pneumococcal Conjugate Vaccine Against Vaccine-type Radiologically-confirmed Community-acquired Pneumonia in Adults >/= 65 Years of Age
Record updated
11 May 2026